SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Cream

Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity

The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream alleviates itch and improves disease activity in adults with atopic dermatitis (AD), while also examining associated changes in skin and serum biomarkers. 

The research team conducting the open-label, single-arm trial looked at 46 patients with moderate AD and significant pruritus. Patients received ruxolitinib cream twice daily for 28 days. According to the results, the treatment provided fast and significant itch relief: current itch intensity (mPP-NRS) improved by a mean of 2.3 points within 15 minutes of the first application, with peak improvements of 4.2 points at 4 to 6 hours. Worst itch over 24 hours improved by 3.4 points by day 2 and 5.7 points by day 29.

The AD improved in parallel. By day 29, 77% of patients achieved IGA-defined success, 96% reached EASI-75, and mean affected body surface area decreased from 9.5% at baseline to 0.5%. Adverse events were mild, with no treatment interruptions. Ruxolitinib was well tolerated.

"Ruxolitinib cream downregulated key skin and serum biomarkers associated with AD pathophysiology, demonstrating rapid molecular effects in conjunction with clinical effects," the authors wrote. "This single-arm study indicates that ruxolitinib cream offers an effective, well-tolerated option for rapid itch relief in patients with AD with evidence of a trend toward the restoration of normal skin characteristics."

Source: Bisonnette R, et al. JID Innovations. 2025. Doi:10.1016/j.jid.2025.10.613